Buradasınız

Anasayfa » Content

Kronik Böbrek Hastalığı Anemisi

Anemia in Chronic Kidney Disease

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2005

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Anemia that is a main complication of chronic kidney disease affects not only the patient's quality of life, but also morbidity and mortality. The primary cause of anemia in kidney patients is erythropoietin deficiency. Erythropoietin which is used at the last decade of 20th century firstly reduces blood transfusions in this patient population. It is necessary to evaluate the patient's iron state before starting erythropoietin treatment. It has been suggested that erythropoietin is efficient in case of sufficient iron storage without infection and inflamation. Multiple studies have shown that eryth-ropoietin treatment has positive effect on left ventricular hypert¬rophy and dilatation, which is the main cause of death in dialysis patients. Currently, neutralizing antierythropoietin antibodies ca¬using resistance to erythropoietin have been discovered.
Bookmark/Search this post with
Abstract (Original Language): 
Kronik böbrek hastalığının önemli bir komplikasyonu olan anemi, yalnızca hastanın yaşam kalitesini değil, aynı zamanda mortali-te ve morbiditeyi de etkiler. Aneminin oluşumunda en önemli faktör eritropoetin eksikliğidir. 1990'lı yıllarda uygulamaya giren erit-ropoetin bu hasta popülasyonunda daha önce sık başvurulan kan transfüzyonu gereksinimini azaltmıştır. Yüksek maliyetli eritropoetin tedavisine başlamadan önce hastanın mutlaka demir durumunun değerlendirilmesi gerekir. Demir depoları yeterli olduğunda, infeksiyon ve inflamasyon gibi problemler olmadığında, eritropo-etin tedavisine uygun cevabın alınacağı kabul edilmektedir. Eritro-poetin tedavisinin, diyaliz hastalarında primer ölüm nedeni olan kardiyovasküler olaylardan sol ventrikül hipertrofisi ve dilatasyonu üzerinde olumlu etkisi olduğu gösterilmiştir. Son zamanlarda erit-ropoetin direncine neden olan nötralize edici antieritropoetin anti¬korların varlığından bahsedilmektedir.
FULL TEXT (PDF): 
PDF icon pdf_tndt_519.pdf
  • 2
51-56
  • Turkish

REFERENCES

References: 

1. Nephrol Dial Transplant (2004) 19 (Suppl 2): ii2-ii5 Section I. Anemia evaluation.
2. Himmelfarb J. Hematologic manifestations of renal failure. In: Greenberg A (ed), Primer on Kidney Disease. 3rd ed, Canada 2001, pp 438-446.
3. Egrie JC, Strickland TW, Lane J, Aoki K, Cohen AM, Smalling R. Characterization and biological effects of recombinant human erythropoietin. Immunobiology 1986;172:213-224.
4. Eschbach JW. Anemia in chronic renal failure. In: Johnson RJ, Fe-ehally J (eds), Comprehensive Clinical Nephrology. 2nd ed,
Mosby, Spain 2003, pp 905-912.
5. Zittoun J, Zittoun R. Modern clinical testing strategies in cobala-min and folate deficiency. Semin Hematol 1999;36:35-46.
6. Nakamura S, Sasaki O, Nakahama H, Inenaga T, Kimura G. Left ventricular hypertrophy is a risk factor independent of hypertension in survival of hemodialyzed patients. Ren Fail 2002;24:175-86.
7. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996;27:347-54.
8. Xue JL, St Peter WL, Ebben JP, Everson SE, Collins AJ. Anemia treatment in the pre-ESRD period and associated mortality in el¬derly patients. Am J Kidney Dis 2002;40:1153-1161.
9. Kazmi WH, Kausz AT, Khan S, Pereira BJG. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis
2001;37:743-9.
10. Hutchinson F, Jones WJ. A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal
disease. Am J Kidney Dis 1997;29:651-7.
11. Fletes R, Lazarus M, Gage J, Chertow BM. Suspected iron dextran related adverse drug events in hemodialysis patients. Am J Kid¬ney Dis 2001;37:743-9.
12. Eschbach JW, Deorea P, Adamson J, et al. NKF-DOQI Clinical Practice Guidelines for the Treatment of Anemia of Chronic Re¬nal Failure. Am J Kidney Dis 2001;37(suppl 1): s182-s238.
13. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and great potency than re-combinant human erythropoietin. Exp Hematol 2003;31:290-9.
14. Nissenson AR. Novel erythropoiesis stimulating protein for managing the anemia of chronic kidney disease. Am J Kidney Dis 2001;38:1390-7.
15. Council on Food and Nutrition, Committee on Iron Deficiency. Iron Deficiency in the United States. JAMA 1968;203: 119-24.
16. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR Egrie JC. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Ann Intern Med 1989;111:992-1000.
17. Means RT, Olsen NJ, Krantz SB, Dessypris EN, Graber SE, Stone WJ. Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin: clinical and in vitro results. Arthritis Rheum 1989;32:638-42.
18. Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia
and epoetin therapy. N Engl J Med 2004;351:1385-7.

Thank you for copying data from http://www.arastirmax.com